

Increasing resistance to nalidixic acid in *Shigella* subgroups in a comparative study between 2001–2003 and 2004–2006

Mamishi S, Mashoori N, Mahboobi N, Pour Akbari B

ABSTRACT

Introduction: The *Shigella* spp. is an organism with an ongoing changing resistance pattern to different antibiotics, thus making its appropriate treatment difficult. Nalidixic acid has been one of the most common agents used for the treatment of shigellosis. Recently, some studies have reported an emerging resistance to this agent.

Methods: In this study, we compared the resistance of *Shigella* isolates during the period 2001–2003 with the period 2004–2006.

Results: *Shigella* spp. resistance was increased totally and in each subgroup, except for *Shigella sonnei*.

Conclusion: Our results showed an increasing resistance of the *Shigella* spp., thus identifying an emergent need for an alternative agent for the treatment of shigellosis in future.

Keywords: antimicrobial resistance, dysentery, nalidixic acid, *Shigella* spp., shigellosis

Singapore Med J 2009;50(8):791-793

INTRODUCTION

Shigellosis is one of the most common causes of dysentery in children, leading to significant mortality and morbidity. Knowing the antimicrobial resistance patterns of the *Shigella* spp. will enable appropriate treatment to be possible, leading to a decrease in the duration, severity and transmission of the disease. However, resistance and sensitivity patterns of *Shigella* subgroups change over time. Therefore, some of the antimicrobial agents that once were the best choice of treatment have lost their efficacy over time. Nalidixic acid is a member of fluoroquinolones that was frequently used in the treatment of shigellosis in the past, especially in children. Unfortunately, some

Table I. Prevalence of *Shigella* subgroups during the periods, 2001–2003 and 2004–2006.

<i>Shigella</i> subgroups	No. (%) in 2001–2003	No. (%) in 2004–2006
<i>Shigella flexneri</i>	88 (49.7)	38 (26.2)
<i>Shigella sonnei</i>	69 (39.0)	101 (69.7)
<i>Shigella dysenteriae</i>	15 (8.5)	4 (2.8)
<i>Shigella boydii</i>	5 (2.8)	2 (1.4)
Total	177 (100)	145 (100)

studies have reported a growing resistance to this antibiotic recently.⁽¹⁻⁹⁾ In this study, we compared the resistance and sensitivity of the *Shigella* spp. and its subgroups to nalidixic acid at the Tehran Paediatrics Centre, a referral paediatrics hospital, between two periods, 2001–2003 and 2004–2006.

METHODS

From the 7,200 stool samples submitted to the Microbiology Laboratory of Tehran Paediatrics Centre, Iran, 322 *Shigella* isolates were identified, 177 isolates from March 2001 to February 2003, and 145 isolates from March 2004 to February 2006. Only one *Shigella* isolate per patient per diarrhoeal episode was included in the analysis. All stool samples were obtained from children under 12 years of age. Samples were inoculated on *Salmonella-Shigella* (SS) agar and eosin methylene blue agar, and incubated at 37°C for 1–5 days. The serotypes of all *Shigella* isolates were determined with commercially-variable polyclonal antisera against all *Shigella* serotypes. The *Shigella* strains were subcultured on McConkey agar plates, and serological tests were performed by the slide agglutination method. The susceptibilities of all isolates to different antibiotics were determined by the disc diffusion method, as recommended by the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards), with commercial antimicrobial discs. The antibiotic discs used in this study was nalidixic acid.^(10,11) Results was interpreted as either sensitive, intermediate or resistant. In our study,

Infectious Disease Research Centre, Tehran Paediatrics Centre, Tehran University of Medical Sciences, Dr Gharib Avenue, Bagher Khan Street, Tehran, Iran

Mamishi S, MD
Head

Mashoori N
Medical Student

Mahboobi N
Medical Student

Pour Akbari B, MS
Researcher

Correspondence to:
Ms Negar Mashoori
16th West Unit,
No 10,
2nd East Alley,
North Varzy Avenue,
Ferdows Street,
Sadeqye Square,
Tehran,
Iran
Tel: (98) 21 4411 2362
Fax: (98) 21 8879 5557
Email: negar_1400
@yahoo.com

Table II. *Shigella* subgroups susceptibility pattern during the periods, 2001–2003 and 2004–2006.

<i>Shigella</i> subgroups	Prevalence in 2001–2003 (%)		Prevalence in 2004–2006 (%)	
	Sensitive	Resistant	Sensitive	Resistant
<i>Shigella flexneri</i>	89.9	10.1	86.9	13.1
<i>Shigella sonnei</i>	76.9	23.1	84.4	15.6
<i>Shigella dysenteriae</i>	81.3	18.8	75	25
<i>Shigella boydii</i>	100	0	50	50

we considered both intermediate and resistant results as resistant.

RESULTS

Among *Shigella* isolates obtained in 2001–2003, the most common subgroup was *Shigella (S.) flexneri* (49.7%), followed by *S. sonnei* (39.0%), *S. dysenteriae* (8.5%) and *S. boydii* (2.8%). In 2004–2006, the most prevalent subgroup was *S. sonnei* (69.7%), followed by *S. flexneri* (26.2%), *S. dysenteriae* (2.8%) and *S. boydii* (1.4%) (Table I). *Shigella* subgroups in 2001–2003 were 86.2% sensitive and 13.8% resistant to nalidixic acid, compared to results in 2004–2006 which was 84.5% and 15.5% for sensitivity and resistance, respectively. Susceptibility patterns according to each subgroup are shown in Table II.

DISCUSSION

Nalidixic acid has been one of the most appropriate antibiotics in the treatment of shigellosis for years because of its cost-effectiveness and accessibility. But antimicrobial therapy against shigellosis has become very limited because of its changing resistance pattern. Agents such as ampicillin, chloramphenicol and bactrim, which once were the choice for treatment of shigellosis, have lost their efficacy. Recently some degrees of resistance of *Shigella* subgroups to nalidixic acid have been reported from various parts of the world, especially in this region, indicating that these antibiotics is going to lose its effectiveness.^(1-6,8,9,11) In one study on 184 *S. sonnei* isolates in Bangladesh, more than 60% of the strains were resistant to nalidixic acid.⁽²⁾ In another study on *Shigella* serogroups in Iran, the total resistance of *Shigella* spp. to nalidixic acid was 4.87% (4.91% for *S. sonnei* and 6.25% for *S. flexneri*).⁽¹¹⁾ In our study, by comparing the susceptibility during two periods, 2001–2003 and 2004–2006, we showed that the sensitivity of the *Shigella* subgroups had decreased from 86.2% to 84.5%, and the resistance rate had increased from 13.8% to 15.5%, although this pattern was not similar among all subgroups, where *S. sonnei* sensitivity had increased.

Although our results were not statistically significant, it corroborated with other studies. In one Korean study,

resistance to nalidixic acid showed a significant increase from 6% of the isolates obtained during the period 1980–1986 to 86% of the isolates obtained during the period 1998–2000.⁽⁴⁾ In some other studies, resistance to nalidixic acid has been reported to be 60%–70%.^(2,4) In another study, oral nalidixic acid failed clinically in 35% and microbiologically in 28.4% of 14 children, as compared with no clinical and microbiological failure in 25 children who were treated with oral azithromycin.⁽⁵⁾ In a few studies, *S. sonnei* was the most common subgroup mentioned as being resistant to nalidixic acid.^(2,4,7) Resistance to nalidixic acid first appeared in an *S. sonnei* isolate in 1997, and then in all *S. sonnei* isolates from 1998 to 1999. In the Korean study, 138 *S. sonnei* isolates were analysed in which nalidixic acid resistance was found in 86% of the isolates.⁽⁴⁾ Significant nalidixic acid-resistant *S. dysenteriae* has been reported in some studies.^(6,9,12) In our study, *S. dysenteria* and *S. boydii* showed the most change in the sensitivity pattern, although the changes were not statistically significant. However, we showed that the resistance rate of *Shigella* isolates is increasing in this region. Hence, resistance to nalidixic acid should be taken into account as a problem for the treatment of shigellosis in the near future. Another probable good option for treatment of shigellosis would be azithromycin, which has been reported in some studies as an alternative therapy.⁽⁵⁾ Further investigation is required in this field.

ACKNOWLEDGEMENT

We gratefully thank the Microbiology Laboratory of Tehran Paediatrics Centre, Iran, for their cooperation.

REFERENCES

- Ashkenazi SH, Levy I, Kazaronovski V, Samra Z. Growing antimicrobial resistance of *Shigella* isolates. *J Antimicrob Chemother* 2003; 51:427-9.
- Talukder KA, Islam Z, Dutta DK, et al. Antibiotic resistance and genetic diversity of *Shigella sonnei* isolated from patients with diarrhoea between 1999 and 2003 in Bangladesh. *J Med Microbiol* 2006; 55(Pt 9):1257-63.
- Kreskent M, Wiedemann B. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin. *Antimicrob Agents Chemother* 1988; 32:1285-8.
- Jeong YS, Lee JC, Kang HY, et al. Epidemiology of nalidixic acid resistance and TEM-1- and TEM-52-mediated ampicillin

- resistance of *Shigella sonnei* isolates obtained in Korea between 1980 and 2000. *Antimicrob Agents Chemother* 2003; 47:3719-23.
5. Miron D, Torem M, Merom R, Colodner R. Azithromycin as an alternative to nalidixic acid in the therapy of childhood shigellosis. *Pediatr Infect Dis J* 2004; 23:367-8.
 6. Ruiz J, Gómez J, Navia MM, et al. High prevalence of nalidixic acid resistant, ciprofloxacin susceptible phenotype among clinical isolates of *Escherichia coli* and other Enterobacteriaceae. *Diagn Microbiol Infect Dis* 2002; 42:257-61.
 7. Seol SY, Kim YT, Jeong YS, et al. Molecular characterization of antimicrobial resistance in *Shigella sonnei* isolates in Korea. *J Med Microbiol* 2006; 55(Pt 7):871-7.
 8. Naik DG. Prevalence and antimicrobial susceptibility patterns of *Shigella* species in Asmara, Eritrea, northeast Africa. *J Microbiol Immunol Infect* 2006; 39:392-5.
 9. Hoge CW, Bodhidatta L, Tungtaem C, Echeverria P. Emergence of nalidixic acid resistant *Shigella dysenteriae* type 1 in Thailand: an outbreak associated with consumption of a coconut milk dessert. *Int J Epidemiol* 1995; 24:1228-32.
 10. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests: Approved standard M2-A7. Villanova, PA: NCCLS, 2000.
 11. Farshad Sh, Sheikhi R, Japoni A, Basiri E, Alborzi A. Characterization of *Shigella* strains in Iran by plasmid profile analysis and PCR amplification of ipa genes. *J Clin Microbiol* 2006; 44:2879-83.
 12. Munshi MH, Sack DA, Haider K, et al. Plasmid-mediated resistance to nalidixic acid in *Shigella dysenteriae* type 1. *Lancet* 1987; 2:419-21.



Orthopaedic MRI Update

*International Skeletal Society Regional Outreach Program,
1-2 Feb 2010*

*12th Annual Scientific Meeting of the Asian Musculoskeletal Society,
Feb 3-4, 2010. Muscat, Oman.*

Organising Chairman: Dr Khamis Al Muzahmi

Scientific Chairman: Prof. Wilfred CG Peh

www.ams2010.com

